342405-40-7

Usage

Molecular Weight

223.25 g/mol

Physical State

White to off-white solid

Application

Commonly used as an intermediate in the synthesis of pharmaceutical compounds

Derivative

Derived from thiazole

Usage

Employed in the development of drugs for various medical conditions

Purity Level

Indicated by "97" in its name, denoting a high purity level of 97%

Suitability

Suitable for research and industrial applications

Handling Precautions

Important to handle with care due to potential health hazards

Storage

Should be stored in a well-ventilated area

Upstream product

• 7357-70-2 Cyanothioacetamide 
• 403-29-2 2-bromo-4'-fluoroacetophenone 

Downstream Products

• 1032228-82-2 C₁₇H₁₂FN₅S 
• 1314891-59-2 N-(2-(4-(4-fluorophenyl)thiazol-2-yl)propyl)-3-(5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl)benzamide 
• 1421511-51-4 N-(4-(trifluoromethyl)phenyl)-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-50-3 N-(3-(trifluoromethyl)phenyl)-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-49-0 N-(4-chlorophenyl)-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-48-9 N-(3-chlorophenyl)-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-47-8 N-(2-chlorophenyl)-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-46-7 N-p-tolyl-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-45-6 N-m-tolyl-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 
• 1421511-44-5 N-phenyl-2-cyano-2-(4-(4-fluorophenyl)thiazol-2-yl)acetamide 

Relevant academic research and scientific papers

A facile route to the 6-hetaryl substituted pyrrolo[1,2-a]thieno[3,2-e]pyrimidine derivatives

Hitherto unknown 6-hetaryl-4,5,7,8-tetrahydropyrrolo[1,2-a]thieno[3,2-e]pyrimidine-4,7-diones (7a-7g) were prepared by reaction of ethyl 2-aminothiophene-3-carboxylates 5 with 4-chloro-2-hetaryl-3-oxobutanonitriles 4 in DMF at 100°C. When the same reagents were treated in the presence of triethylamine, a dependence of the reaction pathway on the nature of the hetaryl substituent in chloronitrile component was observed. This was explained in terms of steric factors.

MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER

Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.

COMPOUNDS AND METHODS for the inhibition of HDAC

Disclosed are compounds having the formula: wherein X1, X2, X3, R1, R2, R3, R4, Y, A, Z, L and n are as defined herein, and methods of making and using the same.

AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS

The present invention is related to azole derivatives notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such azole derivatives. Said azole derivatives are modulators of the protein kinase signalling pathways, particularly the one involving c-Jun N-terminal kinase and/or Glycogen Kinase Synthase 3. The present invention is furthermore related to novel azole derivatives as well as to methods of their preparation. X is O, S or NR0, with R0 being H or an unsubstituted or substituted C1 -C6 alkyl; A is 2-pyridyl, 3-pyridyl, 4-pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or triazinyl group.